


SAGE-718

First-in-Class NMDA Receptor Modulator



- Novel, proprietary, oral, first-in-class, oxysterol-based positive allosteric modulator (PAM) of the NMDA receptor
- Strong preclinical basis for role of NMDA receptor system in cognition
- Multiple disease entities associated with low NMDA function, including Huntington's, ADHD, and Alzheimer's
- Currently in Phase 1 clinical development